Earnings Call Summary | Travere Therapeutic(TVTX.US) Q1 2024 Earnings Conference
Earnings Call Summary | Travere Therapeutic(TVTX.US) Q1 2024 Earnings Conference
The following is a summary of the Travere Therapeutics, Inc. (TVTX) Q1 2024 Earnings Call Transcript:
以下是Travere Therapeutics, Inc.（TVTX）2024年第一季度業績電話會議記錄摘要：
Financial Performance:
財務業績：
Travere recorded Q1 2024 total revenue of $41.4 million, up from $30.9 million in the same period in 2023.
The company sees a net loss of $136.1 million, or $1.76 per basic share, more significant than last years' $86.3 million or $1.27 per basic share.
The firm's cash and cash equivalents and marketable securities stood at $441 million as of March 2024.
Travere的2024年第一季度總收入爲4140萬美元，高於2023年同期的3,090萬美元。
該公司預計淨虧損1.361億美元，合每股基本虧損1.76美元，比去年的8,630萬美元或每股基本股1.27美元更大。
截至2024年3月，該公司的現金和現金等價物以及有價證券爲4.41億美元。
Business Progress:
業務進展：
FILSPARI continues to grow in the US market with 35% growth over the last quarter.
The supplemental New Drug Application (sNDA) of FILSPARI is priority-reviewed by the FDA.
The Phase 3 HARMONY study has been initiated for pegtibatinase, projected to become the new standard in the HCU market.
The growth of FILSPARI will continue to be driven by improved labeling and KDIGO guidelines.
The company has pursued other paths for FSGS treatment and started the Phase III Harmony Study related to the $65 million in-process R&D expense.
FILSPARI在美國市場繼續增長，上個季度增長了35％。
FILSPARI的補充新藥申請（snDa）已通過美國食品藥品管理局的優先審查。
聚乙二醇酶的第三階段HARMONY研究已經啓動，預計將成爲HCU市場的新標準。
標籤和KDIGO指南的改善將繼續推動FILSPARI的增長。
該公司已採取其他途徑進行FSGS治療，並啓動了與6500萬美元在制研發費用相關的第三期和諧研究。
More details: Travere Therapeutic IR
更多詳情： Travere 紅外線治療
Tips: For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
提示：欲了解更多詳情，請訪問投資者關係網站。本文僅供投資者參考，不構成任何投資建議。
譯文內容由第三人軟體翻譯。